NCT06943521 2025-12-11A Study of MT-4561 in Patients With Various Advanced Solid TumorsTanabe Pharma America, Inc.Phase 1/2 Recruiting27 enrolled
NCT03093116 2025-07-10TRIDENT-1Turning Point Therapeutics, Inc.Phase 1/2 Recruiting500 enrolled 2 FDA
NCT04985357 2024-11-25Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to DrugsTravera IncWithdrawn
NCT00511862 2021-05-13TheraSphere for the Treatment of Liver MetastasesBoston Scientific CorporationPhase 2 Completed151 enrolled 10 charts
NCT00363051 2013-05-10Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to ChemotherapyNovartisPhase 2 Completed160 enrolled 17 charts